MESSAGE
DATE | 2017-06-12 |
FROM | From: "APhA's Pharmacy Today"
|
SUBJECT | Subject: [Hangout - NYLXS] =?utf-8?q?June_12=2C_2017=3A_Opioid_Crisis_Comp?=
|
From hangout-bounces-at-nylxs.com Mon Jun 12 13:06:19 2017 Return-Path: X-Original-To: archive-at-nylxs.com Delivered-To: archive-at-nylxs.com Received: from www.mrbrklyn.com (www.mrbrklyn.com [96.57.23.82]) by mrbrklyn.com (Postfix) with ESMTP id 31F92163F57; Mon, 12 Jun 2017 13:06:19 -0400 (EDT) X-Original-To: hangout-at-www.mrbrklyn.com Delivered-To: hangout-at-www.mrbrklyn.com Received: by mrbrklyn.com (Postfix, from userid 1000) id 64951163F56; Mon, 12 Jun 2017 13:06:16 -0400 (EDT) Resent-From: Ruben Safir Resent-Date: Mon, 12 Jun 2017 13:06:16 -0400 Resent-Message-ID: <20170612170616.GB26952-at-www.mrbrklyn.com> Resent-To: hangout-at-mrbrklyn.com X-Original-To: ruben-at-mrbrklyn.com Delivered-To: ruben-at-mrbrklyn.com Received: from mail79-155.us1.msgfocus.com (mail79-155.us1.msgfocus.com [81.29.79.155]) by mrbrklyn.com (Postfix) with ESMTP id 167B2160876 for ; Mon, 12 Jun 2017 09:52:02 -0400 (EDT) DKIM-Signature: v=1; a=rsa-sha1; c=relaxed/relaxed; s=msgf; d=msgfocus.com; h=Subject:Message-ID:Reply-To:X-Mailer:To:List-Unsubscribe:From:Date:MIME-Version:Content-Type; bh=SAFW+vCkUx3m50RLaG8jCNL9e40=; b=P8sBLhhBaNST2kw5oO/yXIoNZk3ezH+kNkUL4jPIMpp7eDAWkRzJ4UysXTL/FcB87bulvinVcY7I M22phlZfIrpTEzk+m/FQ6i/B4nWukvUJ8ypobYpxhBLyPsMpk5FYmWpmj8erxBcUqzsTAZ8Z78o7 QsNKVp7GkN2XFuTRK2E= DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=aphanet.org; s=hrs-dkim; t=1497275521; bh=/fvz9/VSzk93VCXCi6iIiEGuHoxKvKaHkXvZVyLxf6Q=; h=Subject:Message-ID:Reply-To:X-Mailer:To:List-Unsubscribe:From: Date:MIME-Version:Content-Type; b=jTqYLZc7ZKKvwWDQ42o8mX10iMbqSqhfDjfz8cOw2fXvPow94Fp1Tg32om+xyXKlQ eBE0l5FAiuOwRuXLSMfDboWeiww9kKqCRq1sC42wwUKrOr6mPwR/v0SQjsDCQNW0Y3 EAmb2u+fSHXDAGe9oGTzx1RRrOkHbKisMtxzW4rE= Message-ID: X-Mailer: MessageFocus v2 launch To: ruben-at-mrbrklyn.com From: "APhA's Pharmacy Today" Date: Mon, 12 Jun 2017 14:52:01 +0100 MIME-Version: 1.0 Subject: [Hangout - NYLXS] =?utf-8?q?June_12=2C_2017=3A_Opioid_Crisis_Comp?= =?utf-8?q?licates_GOP=E2=80=99s_Health_Law_Push?= X-BeenThere: hangout-at-nylxs.com X-Mailman-Version: 2.1.17 Precedence: list Reply-To: APhA's Pharmacy Today List-Id: NYLXS Tech Talk and Politics List-Unsubscribe: , List-Post: List-Help: List-Subscribe: , Content-Type: multipart/mixed; boundary="===============1236529168==" Errors-To: hangout-bounces-at-nylxs.com Sender: "Hangout"
--===============1236529168== Content-Type: multipart/alternative; boundary="--19B22B36DBE374DE6A2953414C"
----19B22B36DBE374DE6A2953414C Content-Type: text/plain; charset="UTF-8" Content-Transfer-Encoding: quoted-printable
Pharmacy Today
http://apha.msgfocus.com/q/17M5Vd9XzezrvlFKijpEuh/wv jfps-savedate-728 http://apha.msgfocus.com/c/1dDzAWS6y7YS0LggWMePHycks Banner JUNE 12, 2017 Top Story logo Opioid Crisis Complicates GOP=E2=80=99s= Health Law Push Wall Street Journal (06/12/17) Nunn, Sharon The nation=E2= =80=99s worsening opioid crisis has made key Republican senators hesitate t= o support legislation dismantling major portions of the Affordable Care Act= (ACA). Several provisions of the ACA allowed millions of Americans seeking= substance-abuse treatment to gain coverage, including through an expansion= of the Medicaid health program. But the House bill repealing the ACA, pass= ed in early May, would roll back that Medicaid expansion beginning in 2020 = and allow... http://apha.msgfocus.com/c/1dDzEWdrYRkmYK0sOlDbqwOq3
emerinsulin-160 http://apha.msgfocus.com/c/1dDzIVyNpAFRWIKEFV1x9vqvE
Drugs & Diseases logo
=E2=96=AA Seizing on opioid crisis, a drug maker lobbies hard for its product
=E2=96=AA WHO targets antimicrobial resistance in new essential medicines list
=E2=96=AA Mismatch-repair deficiency predicts response of solid tumors to PD-1 blocka= de
=E2=96=AA Chi-Med steps closer to Chinese pharma first with drug filing
Practice & Trends logo
=E2=96=AA Opioid dealers embrace the dark web to send deadly drugs
=E2=96=AA Pfizer hikes U.S. prices of 91 drugs by average 20% in 2017
=E2=96=AA Dietary supplement industry outlines new pedigree protocol
=E2=96=AA Robotic pharmacy to open at Kirkland Cancer Center
Laws, Regs & Rulings logo
=E2=96=AA States lead the fight against Trump's contraception rollback
=E2=96=AA NJ governor approves law expanding pharmacy access to opioid antidote
=E2=96=AA Lower drug costs still 'absolute priority' for Trump, Price says
News You Can Use
http://apha.msgfocus.com/c/1dDzMUU8Qk1mUHuQxupSSu2Bf
=E2=96=AA FDA=E2=80=99s new codeine and tramadol warning further restricts use in kids http://apha.msgfocus.com/c/1dDzQUfuh3mRSGf2p3OeBsEGQ =E2=96=AA Misuse and abuse of noncontrolled drugs: It=E2=80=99s not just prescription= opioids anymore http://apha.msgfocus.com/c/1dDzUTAPHMImQEZegDcAkrgMr
http://apha.msgfocus.com/c/1dDzYSWb8w3RODJq8cAW3pSS2
=E2=96=AA FDA approves first generics of atomoxetine (Strattera) for treatment of ADHD http://apha.msgfocus.com/c/1dDA2ShwzfpmMCtBZLZhMouXD
http://apha.msgfocus.com/c/1dDAaQYdqI6mIzXZIULZelJ8P
=E2=96=AA The impact of a retail prescription synchronization program on medication a= dherence http://apha.msgfocus.com/c/1dDAeQjyRrrRGyIbAuakXkleq
http://apha.msgfocus.com/c/1dDAiPEUiaNmExsns3yGGiXk1
=E2=96=AA Report of the APhA Stakeholder Conference on Improving Patient Access to In= jectable Medications http://apha.msgfocus.com/c/1dDAmP0fIU8RCwczjCX2phzpC
http://apha.msgfocus.com/c/1dDAqOlB9DumAuWLbclo8gbvd
=E2=96=AA Resource Guide for Immunization Services http://apha.msgfocus.com/c/1dDAuNGWAmPRytGX2LJJReNAO
junebom http://apha.msgfocus.com/c/1dDAyN2i16bmwsr8Ul85AdpGp
PT_May2017_Cover http://apha.msgfocus.com/c/1dDACMnDrPwRurbkLUwrjc1M0
Top Story
Opioid Crisis Complicates GOP=E2=80=99s Health Law Push Wall Street Journal (06/12/17) Nunn, Sharon
The nation=E2=80=99s worsening opioid crisis has made key Republican senato= rs hesitate to support legislation dismantling major portions of the Afford= able Care Act (ACA). Several provisions of the ACA allowed millions of Amer= icans seeking substance-abuse treatment to gain coverage, including through= an expansion of the Medicaid health program. But the House bill repealing = the ACA, passed in early May, would roll back that Medicaid expansion begin= ning in 2020 and allow insurance companies to charge some people with drug = addictions higher premiums or deny them substance-abuse coverage. Concerns = about those provisions cut into Republican support for the replacement meas= ure in the House. Of the 20 Republicans who voted against the House bill, 1= 6 represent states that saw significant increases in drug-overdose death ra= tes in recent years. Now, the same concerns are emerging as a factor as the= Senate takes up the House bill and ponders how to change it. Some Republic= an senators are pushing to wind down the Medicaid expansion funding more sl= owly. They would have the rollback occur over a 7-year window beginning in = 2020. Lawmakers are also looking at including a pot of money specifically f= or opioid treatment, according to Republican senate aides.
Read More http://apha.msgfocus.com/c/1dDAGLIYSySmspVwDtUN2aDRB | Return to Headlines
Drugs & Diseases
Seizing on opioid crisis, a drug maker lobbies hard for its product New York Times (06/12/17) Goodnough, Abby; Zernike, Kate
Drug manufacturer Alkermes has spent years targeting lawmakers and law enfo= rcement strategies, lobbying them about the benefits of its naltrexone (Viv= itrol) drug as a treatment for opioid addiction. Now, its sales and profile= are rising fast, thanks to its manufacturers=E2=80=99 shrewd use of politi= cal connections, and despite scant science to prove the drug=E2=80=99s effi= cacy. Last month, HHS Secretary Tom Price, praised it as the future of opio= id addiction treatment after visiting the company=E2=80=99s plant in Ohio. = He set off a furor among substance abuse specialists by criticizing its les= s expensive and more widely used and rigorously studied competitors, bupren= orphine and methadone, as medications that "simply substitute" for illicit = drugs. With the Trump administration sending $1 billion in new addiction pr= evention and treatment funds to states over the next 2 years through the 21= st Century Cures Act, Alkermes's marketing has shifted into even higher gea= r. Nearly 700 experts in the field recently wrote a letter to Price asserti= ng that some the company's marketing tactics ignore widely accepted science= . Alkermes executives say they welcome any addiction treatment. They have p= resented their drug as a cleaner alternative to buprenorphine.
Read More http://apha.msgfocus.com/c/1dDAKL4kjidRqoFIv3j8L9fXc | Return to Headlines
WHO targets antimicrobial resistance in new essential medicines list British Medical Journal (06/09/17) Gulland, Anne
The World Health Organization says the antibiotics colistin and some cephal= osporins should only be used when all other treatments have failed, in an e= ffort to combat anti-microbial resistance. In the latest edition of its ess= ential medicines list, updated every 2 years, WHO has grouped antibiotics i= nto three groups=E2=80=94access, watch, and reserve=E2=80=94indicating whic= h can be used for common infections and which should only be used in rare c= ircumstances. WHO recommends that antibiotics in the access group, which in= cludes amoxicillin, be available at all times to treat common conditions. T= he watch group includes antibiotics that are recommended as first or second= choice treatments for a small number of infections. In this group are cipr= ofloxacin to treat cystitis and upper respiratory tract infections which, W= HO says, should be dramatically reduced to avoid further development of res= istance. The third group, reserve, includes antibiotics that should be cons= idered last resort options and used only when all other drugs have failed, = such as for life threatening infections from multidrug resistant bacteria.
Read More http://apha.msgfocus.com/c/1dDASJL1aKURmma6ec5Qd6u8o | Return to Headlines
Mismatch-repair deficiency predicts response of solid tumors to PD-1 blocka= de Science (06/08/17) Le, Dung T.; Durham, Jennifer N.; Smith, Kellie N.; et a= l.
In a new study, researchers report the expansion of a proof-of-concept stud= y that found that colorectal cancers with mismatch repair (MMR) deficiency = were sensitive to immune checkpoint blockade with anti-PD-1 antibodies. The= new study evaluated the efficacy of PD-1 blockade in patients with advance= d MMR-deficient cancers for 12 different tumor types. The data show that ob= jective radiographic responses were seen in more than one-half (53%) of the= patients, while 21% achieved complete responses. The responses, they note,= were durable with median progression-free and overall survival still not r= eached. Functional analysis in a responding patient revealed rapid in vivo = expansion of neoantigen-specific T cell clones that were reactive to mutant= neopeptides found in the tumor. According to the researchers, the findings= "support the hypothesis that the large proportion of mutant neoantigens in= MMR-deficient cancers make them sensitive to immune checkpoint blockade, r= egardless of the cancers' tissue of origin."
Read More http://apha.msgfocus.com/c/1dDAWJ6mBugmkkUi5LubW56dZ | Return to Headlines
Chi-Med steps closer to Chinese pharma first with drug filing Reuters (06/12/17)
Hutchison China MediTech, the Shanghai-based drugmaker listed in London, re= ported on Monday that China's Food and Drug Administration will now review = its cancer medicine fruquintinib as a treatment for advanced colorectal can= cer. The move triggers a milestone payment of $4.5 million from U.S. partne= r Eli Lilly to the Chinese firm, which is commonly known as Chi-Med. Chi-Med and Lilly also aim to win approval for fruquintinib in the United S= tates, which would make it the first modern drug developed in China to be s= old on the international market. Hopes for the drug, which starves tumors o= f blood supply, received a major boost in March when a late-stage clinical = trial produced strongly positive results in colon cancer. The drug is also = being developed for non-small cell lung cancer and another study in gastric= cancer is due to start soon.
Read More http://apha.msgfocus.com/c/1dDB0IrI2dBRijEtXkSxF3IjA | Return to Headlines
Practice & Trends
Opioid dealers embrace the dark web to send deadly drugs New York Times (06/11/17) Popper, Nathaniel
In a growing number of arrests and opioid overdoses, law enforcement offici= als say, the drugs are being bought online. Internet sales have allowed pow= erful synthetic opioids such as fentanyl to reach people through small pack= ages in the mail. The authorities have been frustrated in their efforts to = crack down on the trade because these sites generally exist on the so-calle= d dark web, where buyers can visit anonymously using special browsers and m= ake purchases with virtual currencies like Bitcoin. Largely because of thei= r potency, synthetic opioids have become the fastest-growing cause of the o= verdose epidemic. Just a few flakes of fentanyl can be fatal. Their deadly = efficiency also makes them ideal for sale online. Unlike heroin and prescri= ption opioid analgesics, which are relatively bulky, enough fentanyl to eff= ect nearly 50,000 people can fit in a standard first-class envelope. The au= thorities say these markets account for a small proportion of the overall t= raffic in most drugs. But when it comes to synthetic opioids, many authorit= ies tracking the traffic say that dark web markets have quickly assumed a m= ore prominent role.
Read More http://apha.msgfocus.com/c/1dDB4HN3sWXmgioFOUgTo2kpb | Return to Headlines
Pfizer hikes U.S. prices of 91 drugs by average 20% in 2017 Reuters (06/02/17) Grover, Natalie
Pfizer has increased the list price of 91 medicines in the United States by= an average of 20% thus far in 2017, according to a new report. Data seen b= y the Financial Times indicate the company raised the list price of the dru= gs by 5%=E2=80=9313% on June 1, after also increasing prices in January. A = company spokesperson noted, "For Pfizer's U.S. biopharma business, as of th= e first quarter, the weighted average net selling price increase year-to-da= te is 4%," referring to prices after discounts and rebates, rather than lis= t prices.
Read More http://apha.msgfocus.com/c/1dDB8H8oTGiReh8RGtFf70WuM | Return to Headlines
Dietary supplement industry outlines new pedigree protocol Drug Store News (06/01/17) Johnsen, Michael
The SIDI Work Group=E2=80=94a coalition of the Consumer Healthcare Products= Association, the Council for Responsible Nutrition (CRN), and the United N= atural Products Alliance=E2=80=94issued an updated draft of the "Standardiz= ed Information on Dietary Ingredients Protocol." According to Duffy Mackay,= chair of the SIDI Work Group executive committee and senior vice president= , scientific and regulatory affairs, CRN, "The SIDI Work Group convened reg= ularly over several months developing an updated draft that addresses new f= ood safety regulations implemented since version 2.1 was released in 2008. = We welcome comments from industry stakeholders and regulatory officials for= consideration as we finalize this next edition of the Protocol, slated for= release by the end of 2017." The Protocol presents an outline representing= the type and scope of information about a dietary ingredient that an ingre= dient supplier typically needs to provide to a manufacturer. The primary ob= jective of the Protocol is to recommend a standard format for presenting th= is information, so that information exchange can be done in a simplified an= d streamlined manner. The SIDI Work Group is seeking feedback from industry= stakeholders and regulators by July 3. The draft Protocol and comment form= are available here http://apha.msgfocus.com/c/1dDBcGtKkpEmcfT3y33APZyAn.
Read More http://apha.msgfocus.com/c/1dDBgFP5L8ZRaeDfpCrWyYaFY | Return to Headlines
Robotic pharmacy to open at Kirkland Cancer Center Jackson Sun (Tennessee) (05/20/17) Faris, Maranda
The Kirkland Cancer Center in Jackson, TN, recently opened its new robotic = pharmacy. The pharmacy will allow medications to be mixed more accurately i= n a liquid form and decrease the amount of waste from other forms of medica= tion. The new pharmacy also allows more patients to visit the Jackson and t= he Kirkland Cancer Center, rather than having to go out of state for treatm= ents. "You don't have to go somewhere else. You may choose to, but there ar= e many things that you can do right here at home, and this is one of the la= test advances," West Tennessee Healthcare Foundation President Frank McMeen= said. "You don't have to go to Houston, or Wisconsin or Ohio. It puts us i= n a whole other league of cancer facilities." McMeen said the pharmacy is b= eing named after Eugene Reese, MD, and his wife, Elaine. "The pharmacy has = become more and more involved in compounding the medicines, mixing them and= getting them ready for patients to be treated," Reese said. "The pharmacy = has become a much more important role in the treatment of oncology patients= than it was 40 years ago."
Read More http://apha.msgfocus.com/c/1dDBkFarbSlm8dnrhbQihWMLz | Return to Headlines
Laws, Regs & Rulings
States lead the fight against Trump's contraception rollback New York Times (06/10/17) Stolberg, Sheryl Gay
With the Trump administration planning to roll back the Affordable Care Act= (ACA) mandate that employers cover contraceptives, the battle over the iss= ue is shifting to the states. Currently, 28 states have some type of "contr= aceptive equity" law, aimed at making it cheaper and more accessible. Gov. = Brian Sandoval of Nevada on June 10 signed a measure requiring insurers to = cover 12 months of contraception at a time, with no copayment. Several stat= es are expanding access by requiring insurers to cover a year=E2=80=99s sup= ply of contraceptives at a time, as opposed to the customary 3 months. In W= ashington, Gov. Jay Inslee last month signed a bill that would do just that= , and Gov. John Hickenlooper of Colorado signed a similar bill last week. L= awmakers in Massachusetts and New York are also considering "contraceptive = equity bills." The Trump administration has drafted a far-reaching rule tha= t would greatly expand the number of employers and insurers that could qual= ify for exemptions from the ACA's contraceptive mandate by claiming a moral= or a religious objection. Hundreds of thousands of women, many of them poo= r, could lose access to no-cost birth control if the rule goes into effect.
Read More http://apha.msgfocus.com/c/1dDBoEvMCBGR6c7D8LeE0VoRa | Return to Headlines
NJ governor approves law expanding pharmacy access to opioid antidote NJ Spotlight (06/12/17) Stainton, Lilo
Gov. Chris Christie of New Jersey signed a law Friday that would allow phar= macies of all sizes to sell naloxone, which is easy to administer as a shot= or nasal spray that can quickly reverse a potentially deadly reaction to h= eroin or prescription drugs. "Expanding access to nalaxone will help save l= ives and allow those who are suffering from addiction a second chance to ge= t the treatment they need to win their battle" with the disease, said Sen. = Joe Vitale (D-Middlesex), who first introduced a proposal to expand drug st= ore sales in November 2015. Vitale noted access to the antidote was limited= in the past, especially for civilians who were not first responders. "But = the antidote can be administered safely and swiftly by others, including fa= mily members, and providing access to it at the pharmacy can mean the diffe= rence between life and death," he said. A growing number of community pharm= acies, including CVS and Walgreens, announced plans last year to expand sal= es of the medicine to patients without specific orders from a doctor to hun= dreds of stores in New Jersey. The new law makes clear that smaller, independent pharmacies can do the sam= e, and directs a doctor in the ranks of the state Department of Health to s= tep in and provide the required standing order if the pharmacy does not hav= e a physician to do so.
Read More http://apha.msgfocus.com/c/1dDBsDR83l2m4aRP0kCZJU0WL | Return to Headlines
Lower drug costs still 'absolute priority' for Trump, Price says Bloomberg (06/08/17) Edney, Anna
HHS Secretary Tom Price, MD, on June 8 told the Senate Finance Committee th= at President Trump has asked his agency for recommendations on policies tha= t would reduce the costs of medications. Price said he instructed CMS, FDA,= and the Health Resources and Services Administration to come up with propo= sals. He has also been meeting with pharmacists, care providers, and PBMs i= n recent weeks to discuss ideas for making drugs more affordable. At the Se= nate hearing, Price declined to answer a separate question about whether th= e administration will fund cost-sharing reduction payments made to insurers= to help reduce low-income Americans' health expenses.
Read More http://apha.msgfocus.com/c/1dDBACxOUNJm08mcJtpHbRf7X | Return to Headlines
Abstract News =C2=A9 Copyright 2017 INFORMATION, INC. http://apha.msgfocus.com/c/1dDBEBTalx4QY76oB2O2UPRdy Powered by Information, Inc. http://apha.msgfocus.com/c/1dDBIBevMgqlW5QAsCcoDOtj9
careerctr-728 http://apha.msgfocus.com/c/1dDBMAzRcZLQU4AMkbAKmN5oK
http://apha.msgfocus.com/c/1dDBQzVcDJ7lS3kYbKZ65LHul
----19B22B36DBE374DE6A2953414C Content-Type: text/html; charset="UTF-8" Content-Transfer-Encoding: quoted-printable
"http://www.w3.org/TR/html4/loose.dtd">
Pharmacy Today width=3D"728"> =20=20=20=20 >=20=20=20=20=20=20=20=20 g=3D0 width=3D"728"> :center;" id=3D"TDLinkBar" bgcolor=3D"#ffffff" valign=3D"top" colspan=3D"2"= align=3D"center"> vlFKijpEuh/wv">View this email online. | =20=20=20=20 inkBar" bgcolor=3D"#ffffff" valign=3D"top" colspan=3D"2"> rOKjzW" target=3D"_blank"> s/JFPS-2017-Save-The-Date-728x90.png" hspace=3D"0" vspace=3D"0" border=3D"0= " alt=3D"jfps-savedate-728" /> | mages/banner.jpg" alt=3D"Banner" width=3D"728" height=3D"190" hspace=3D"0" = vspace=3D"0" border=3D"0" usemap=3D"#bannerMap">
| ing=3D"0" border=3D"0"> &= nbsp; | ong>JUNE 12, 2017 | olspan=3D"2" style=3D"height: 5px;"> | |
| =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 " > ing=3D"0" border=3D"0"> idth=3D"728"> apha_daily/images/top-story.gif" border=3D"0" alt=3D"Top Story" width=3D"72= 8" height=3D"39" /> | "0" cellpadding=3D"0" border=3D"0"> ign=3D"top" width=3D"350" style=3D"padding: 0px;"> n-bottom:10px;"> ![]() c=3D"http://www.infoinc.com/apha_daily/images/library/1998/laws-3_lg.jpg" a= lt=3D"logo" hspace=3D"0" vspace=3D"0" border=3D"0" style=3D"padding:0px;max= -width:350px;" width=3D"350" />
=20=20=20=20= =20=20=20=20 | le=3D"padding: 5px;" valign=3D"top" width=3D"378"> O= pioid Crisis Complicates GOP’s Health Law Push Wall= Street Journal (06/12/17) Nunn, Sharon The nation’s= worsening opioid crisis has made key Republican senators hesitate to suppo= rt legislation dismantling major portions of the Affordable Care Act (ACA).= Several provisions of the ACA allowed millions of Americans seeking substa= nce-abuse treatment to gain coverage, including through an expansion of the= Medicaid health program. But the House bill repealing the ACA, passed in e= arly May, would roll back that Medicaid expansion beginning in 2020 and all= ow... Read More =3D"margin-top:5px; line-height: 1.75"> =20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | =20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | | | r=3D"#ffffff" align=3D"left" valign=3D"top" colspan=3D"2"> | inkBar" bgcolor=3D"#ffffff" width=3D"424"> ing=3D"0" border=3D"0"> g: 0px;"> apha_daily/images/news.gif" width=3D"424" height=3D"31" border=3D"0" alt=3D= "News You Can Use" /> | g: 0px;"> pacing=3D"0" cellpadding=3D"0" border=3D"0"> g: 0px;" width=3D"128"> | g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to= p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=09 ://apha.msgfocus.com/c/1dDC6xiAmEvlJYjJE2yuZG9QJ" target=3D"_blank"> c=3D"http://www.infoinc.com/apha_daily/images/pharmacy-today.gif" border=3D= "0" alt=3D"" /> =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20 | g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to= p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=09 ://apha.msgfocus.com/c/1dDCmuFY5zTlBTiv6k7TTACd7" target=3D"_blank"> c=3D"http://www.infoinc.com/apha_daily/images/drug-info-line.gif" border=3D= "0" alt=3D"" /> =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20 | g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to= p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=09 ://apha.msgfocus.com/c/1dDCutmEX2AlxQMSPsUBlxQoj" target=3D"_blank"> c=3D"http://www.infoinc.com/apha_daily/images/japha.gif" border=3D"0" alt= =3D"" /> =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20 | g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20 | g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to= p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=09 ://apha.msgfocus.com/c/1dDCCs3lOvhltOhgyBHiNv4zv" target=3D"_blank"> c=3D"http://www.infoinc.com/apha_daily/images/Education_Icon.png" border=3D= "0" alt=3D"" /> =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20 | g: 0px; padding-top: 0px; padding-bottom: 10px;" width=3D"128" valign=3D"to= p">=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=09 ://apha.msgfocus.com/c/1dDCKqK2FXYlpLLEhKu0fsiKH" target=3D"_blank"> c=3D"http://www.infoinc.com/apha_daily/images/PT_Resources_Icon.png" border= =3D"0" alt=3D"" /> =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20 | g: 10px; padding-top: 0px; padding-left: 10px;" valign=3D"top">=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20 |
| | inkBar" bgcolor=3D"#ffffff" width=3D"300" valign=3D"top"> | r=3D"#ffffff" align=3D"left" valign=3D"top" colspan=3D"2"> | =20 inkBar" bgcolor=3D"#ffffff" valign=3D"top">=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20=20= =20=20=20=20=20=20=20=20=20=20 com/apha_daily/images/APhA.TopStory.gif" border=3D"0" alt=3D"Top Story" /><= br>
Opioid Crisis Complicates GOP’s Health Law Push Wa= ll Street Journal (06/12/17) Nunn, Sharon The nation&rsquo= ;s worsening opioid crisis has made key Republican senators hesitate to sup= port legislation dismantling major portions of the Affordable Care Act (ACA= ). Several provisions of the ACA allowed millions of Americans seeking subs= tance-abuse treatment to gain coverage, including through an expansion of t= he Medicaid health program. But the House bill repealing the ACA, passed in= early May, would roll back that Medicaid expansion beginning in 2020 and a= llow insurance companies to charge some people with drug addictions higher = premiums or deny them substance-abuse coverage. Concerns about those provis= ions cut into Republican support for the replacement measure in the House. = Of the 20 Republicans who voted against the House bill, 16 represent states= that saw significant increases in drug-overdose death rates in recent year= s. Now, the same concerns are emerging as a factor as the Senate takes up t= he House bill and ponders how to change it. Some Republican senators are pu= shing to wind down the Medicaid expansion funding more slowly. They would h= ave the rollback occur over a 7-year window beginning in 2020. Lawmakers ar= e also looking at including a pot of money specifically for opioid treatmen= t, according to Republican senate aides.
=20 com/apha_daily/images/drugs-diseases.gif" border=3D"0" alt=3D"Drugs & Disea= ses" />
Seizing on opioid crisis, a drug maker lobbies hard for its product= b> New York Times (06/12/17) Goodnough, Abby; Zernike, Kate /> Drug manufacturer Alkermes has spent years targeting lawmakers a= nd law enforcement strategies, lobbying them about the benefits of its nalt= rexone (Vivitrol) drug as a treatment for opioid addiction. Now, its sales = and profile are rising fast, thanks to its manufacturers’ shrewd use = of political connections, and despite scant science to prove the drug&rsquo= ;s efficacy. Last month, HHS Secretary Tom Price, praised it as the future = of opioid addiction treatment after visiting the company’s plant in O= hio. He set off a furor among subs |
|
 |
|
|
 |
 |
|
|